Open Access

Identification of the potential therapeutic target gene UBE2C in human hepatocellular carcinoma: An investigation based on GEO and TCGA databases

  • Authors:
    • Zilun Wei
    • Yihai Liu
    • Shuaihua Qiao
    • Xueling Li
    • Qiaoling Li
    • Jinxuan Zhao
    • Jiaxin Hu
    • Zhonghai Wei
    • Anqi Shan
    • Xuan Sun
    • Biao Xu
  • View Affiliations

  • Published online on: April 9, 2019     https://doi.org/10.3892/ol.2019.10232
  • Pages: 5409-5418
  • Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) ranks the third major cause of cancer‑associated mortality globally. Numerous studies have attempted to elucidate the underlying mechanisms of HCC using various biomarkers. In the present study, two expression profiles datasets from Gene Expression Omnibus (GSE76427 and GSE84402) and data associated with liver cancer samples from The Cancer Genome Atlas (TCGA) were downloaded for integrated analysis. Five differentially expressed genes (DEGs) exhibiting high expression, including ubiquitin‑conjugating enzyme 2C (UBE2C), topoisomerase II α, pituitary tumor transforming gene 1, glypican‑3 and polycomb‑repressive complex 1, were selected and considered as candidate genes. Enrichment analysis demonstrated that these genes were associated with Gene Ontology terms of cellular components and molecular functions, including regulation of apoptosis, stabilization of p53 and Anaphase Promoting Complex/Cyclosome (APC/C) (APC/C:Cdc20)‑mediated degradation of Securin. The expression profiles of these genes in HCC, other human malignancies and different human HCC cell lines were validated using GSE14520, GSE3500 and TCGA data. The results confirmed the upregulation of UBE2C in tissues from patients with HCC or other human malignancies and human liver cancer cell lines, compared with the expression levels in the corresponding adjacent non‑tumor tissues and cell lines, respectively. Patients with HCC who exhibited an increased messenger RNA level of UBE2C exhibited a significantly shorter survival time. The results of the present study suggest that the overexpression of UBE2C may be used as a novel prognostic biomarker of HCC.

References

1 

Neumann H, Longo D, Fauci A, Kasper D, Hauser S, Jameson J and Loscalzo J: Harrison's Principles of Internal Medicine. 2011.

2 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Liang HW, Yang X, Wen DY, Gao L, Zhang XY, Ye ZH, Luo J, Li ZY, He Y, Pang YY and Chen G: Utility of miR-133a-3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta-analysis and bioinformatics. Mol Med Rep. 17:14692018.PubMed/NCBI

4 

Yang N, Ekanem NR, Sakyi CA and Ray SD: Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev. 81:62–74. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Kulasingam V and Diamandis EP: Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 5:588–599. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Guo Y, Bao Y, Ma M and Yang W: Identification of key candidate genes and pathways in colorectal cancer by integrated bioinformatical analysis. Int J Mol Sci. 18:E7222017. View Article : Google Scholar : PubMed/NCBI

8 

Liang L, Gao L, Zou XP, Huang ML, Chen G, Li JJ and Cai XY: Diagnostic significance and potential function of miR-338-5p in hepatocellular carcinoma: A bioinformatics study with microarray and RNA sequencing data. Mol Med Rep. 17:2297–2312. 2018.PubMed/NCBI

9 

Zeng T, Wang D, Chen J, Chen K, Yu G, Chen Q, Liu Y, Yan S, Zhu L, Zhou H, et al: AF119895 regulates NXF3 expression to promote migration and invasion of hepatocellular carcinoma through an interaction with miR-6508-3p. Exp Cell Res. 363:129–139. 2018. View Article : Google Scholar : PubMed/NCBI

10 

Gan TQ, Xie ZC, Tang RX, Zhang TT, Li DY, Li ZY and Chen G: Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data. Tumour Biol. 39:10104283176916832017. View Article : Google Scholar : PubMed/NCBI

11 

Zhang L, Huang L, Liang H, Zhang R, Chen G, Pang Y and Feng Z: Clinical value and potential targets of miR-224-5p in hepatocellular carcinoma validated by a TCGA- and GEO- based study. Int J Clin Exp Pathol. 10:9970–9989. 2017.

12 

Grinchuk OV, Yenamandra SP, Iyer R, Singh M, Lee HK, Lim KH, Chow PK and Kuznetsov VA: Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol. 12:89–113. 2018. View Article : Google Scholar : PubMed/NCBI

13 

Wang H, Huo X, Yang XR, He J, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 16:1362017. View Article : Google Scholar : PubMed/NCBI

14 

Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, et al: Gene expression patterns in human liver cancers. Mol Biol Cell. 13:1929–1939. 2002. View Article : Google Scholar : PubMed/NCBI

15 

Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, et al: Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 142:957–966. 2012. View Article : Google Scholar : PubMed/NCBI

16 

Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX and Wang XW: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Dhanasekaran R, Limaye A and Cabrera R: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 4:19–37. 2012.PubMed/NCBI

18 

Guo X, Wang Z, Zhang J, Xu Q, Hou G, Yang Y, Dong C, Liu G, Liang C, Liu L, et al: Upregulated KPNA2 promotes hepatocellular carcinoma progression and indicates prognostic significance across human cancer types. Acta Biochim Biophys Sin (Shanghai). 51:285–292. 2019. View Article : Google Scholar : PubMed/NCBI

19 

Tong H, Liu X, Li T, Qiu W, Peng C, Shen B and Zhu Z: INTS8 accelerates the epithelial-to-mesenchymal transition in hepatocellular carcinoma by upregulating the TGF-beta signaling pathway. Cancer Manag Res. 11:1869–1879. 2019. View Article : Google Scholar : PubMed/NCBI

20 

Aziz K, Limzerwala JF, Sturmlechner I, Hurley E, Zhang C, Jeganathan KB, Nelson G, Bronk S, Velasco RF, van Deursen EJ, et al: Ccne1 overexpression causes chromosome instability in liver cells and liver tumor development in Mice. Gastroenterology. 2019. View Article : Google Scholar

21 

Bose MV, Gopisetty G, Selvaluxmy G and Rajkumar T: Dominant negative Ubiquitin-conjugating enzyme E2C sensitizes cervical cancer cells to radiation. Int J Radiat Biol. 88:629–634. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Liu YC: Ubiquitin ligases and the immune response. Annu Rev Immunol. 22:81–127. 2004. View Article : Google Scholar : PubMed/NCBI

23 

Williamson A, Wickliffe KE, Mellone BG, Song L, Karpen GH and Rape M: Identification of a Physiological E2 module for the human anaphase-promoting complex. Proc Natl Acad USA. 106:18213–11821. 2009. View Article : Google Scholar

24 

Reddy SK, Rape M, Margansky WA and Kirschner MW: Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation. Nature. 446:921–926. 2007. View Article : Google Scholar : PubMed/NCBI

25 

van Ree JH, Jeganathan KB, Malureanu L and van Deursen JM: Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol. 188:83. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Morikawa T, Kawai T, Abe H, Kume H, Homma Y and Fukayama M: UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy. Int J Clin Exp Pathol. 6:1367–1374. 2013.PubMed/NCBI

27 

Rawat A, Gopal G, Selvaluxmy G and Rajkumar T: Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. Cell Oncol (Dordr). 36:459–467. 2013. View Article : Google Scholar : PubMed/NCBI

28 

Hao Z, Zhang H and Cowell J: Ubiquitin-conjugating enzyme UBE2C: Molecular biology, role in tumorigenesis, and potential as a biomarker. Tumor Biol. 33:723–730. 2012. View Article : Google Scholar

29 

Zhang Y, Han T, Wei G and Wang Y: Inhibition of microRNA-17/20a suppresses cell proliferation in gastric cancer by modulating UBE2C expression. Oncol Rep. 33:2529–2536. 2015. View Article : Google Scholar : PubMed/NCBI

30 

Chang L, Zhang Z, Yang J, McLaughlin SH and Barford D: Atomic structure of the APC/C and its mechanism of protein ubiquitination. Nature. 522:450–454. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Xie C, Powell C, Yao M, Wu J and Dong Q: Molecules in focus: Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. Int J Biochem Cell Biol. 47:113–118. 2014. View Article : Google Scholar : PubMed/NCBI

32 

Rowinsky EK and Donehower RC: Paclitaxel (taxol). N Engl J Med. 332:1004–1014. 1995. View Article : Google Scholar : PubMed/NCBI

33 

Gascoigne KE and Taylor SS: Article: Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell. 14:111–123. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wei, Z., Liu, Y., Qiao, S., Li, X., Li, Q., Zhao, J. ... Xu, B. (2019). Identification of the potential therapeutic target gene UBE2C in human hepatocellular carcinoma: An investigation based on GEO and TCGA databases. Oncology Letters, 17, 5409-5418. https://doi.org/10.3892/ol.2019.10232
MLA
Wei, Z., Liu, Y., Qiao, S., Li, X., Li, Q., Zhao, J., Hu, J., Wei, Z., Shan, A., Sun, X., Xu, B."Identification of the potential therapeutic target gene UBE2C in human hepatocellular carcinoma: An investigation based on GEO and TCGA databases". Oncology Letters 17.6 (2019): 5409-5418.
Chicago
Wei, Z., Liu, Y., Qiao, S., Li, X., Li, Q., Zhao, J., Hu, J., Wei, Z., Shan, A., Sun, X., Xu, B."Identification of the potential therapeutic target gene UBE2C in human hepatocellular carcinoma: An investigation based on GEO and TCGA databases". Oncology Letters 17, no. 6 (2019): 5409-5418. https://doi.org/10.3892/ol.2019.10232